| 1 |
33502001 | Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene. | 2021 Feb |
1 |
| 2 |
34547879 | [Treatment of PCM1-JAK2-positive myeloproliferative neoplasm with eosinophilia using ruxolitinib: a case report]. | 2021 Aug 14 |
1 |
| 3 |
34707996 | Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review. | 2021 |
3 |
| 4 |
32279331 | Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. | 2020 Jul |
1 |
| 5 |
25260694 | Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. | 2015 Feb |
1 |
| 6 |
26202607 | Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. | 2015 Nov |
1 |
| 7 |
23630205 | Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. | 2013 Jun 10 |
1 |
| 8 |
22899477 | Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. | 2012 Aug 16 |
1 |